Prostamax
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Prostamax is a Khavinson tetrapeptide for the prostate — part of the reproductive/hormone corner of the Khavinson short-peptide bioregulator family, alongside Testagen. Site tier is Anecdotal (4 studies, 0 human). The Lys-Glu-Asp-Pro sequence is anchored in a cited study title in the source ( 23221144), one of the few Khavinson-family sequences not carrying a flag on the sequence itself.
What does it do in my body?
Claimed mechanism: like the rest of the Khavinson family, Prostamax is proposed to act via gene-promoter binding in prostate tissue, framed as supporting prostate and urological health.
How can it help me?
- Where the science stands: Site tier Anecdotal (4 studies, 0 human) — all four are family chromatin-mechanism work, not prostate-outcome studies
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-event data exists for Prostamax. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and a peptide marketed on an organ-specific claim it has no clinical outcome data for is an especially easy target for overselling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Prostamax is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Prostamax, and no prostate-outcome human data exists to inform a protocol around. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Prostamax specifically, let alone for a prostate-support outcome.
What should I avoid combining — and what's synergistic?
Prostamax doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Prostamax (Lys-Glu-Asp-Pro / KEDP) is a Khavinson tetrapeptide for the prostate. Its four citations all demonstrate the family’s general chromatin-remodeling mechanism in senile lymphocytes — not a prostate-specific clinical effect. There are no prostate-outcome human studies. Say so plainly.
| Class | Khavinson tetrapeptide — Lys-Glu-Asp-Pro (KEDP) |
| Mechanism (one line) | Claimed to modulate gene expression for prostate / urological tissue support |
| Evidence base | Site tier Anecdotal (4 studies, 0 human) — all four are family chromatin-mechanism work, not prostate-outcome studies |
| Safety record | No AE data specific to Prostamax; family-wide mild profile assumed; OHM grade D / provisional |
| Regulatory status | research_only in the US, not FDA-approved |
What it is
Prostamax is a Khavinson tetrapeptide for the prostate — part of the reproductive/hormone corner of the Khavinson short-peptide bioregulator family, alongside Testagen. Site tier is Anecdotal (4 studies, 0 human). The Lys-Glu-Asp-Pro sequence is anchored in a cited study title in the source ( 23221144), one of the few Khavinson-family sequences not carrying a flag on the sequence itself.
How it works
Claimed mechanism: like the rest of the Khavinson family, Prostamax is proposed to act via gene-promoter binding in prostate tissue, framed as supporting prostate and urological health.
What the research shows
Site tier is Anecdotal (4 studies, 0 human). The four citations are all the family’s chromatin/heterochromatin in-vitro work in senile/elderly lymphocytes — increased sister-chromatid exchanges and pericentromeric heterochromatin decondensation (Dzhokhadze et al. 2012, 23221144; Khavinson/Lezhava/Malinin 2004, 15085253; plus 19359734, 15612551), all.
These demonstrate the family mechanism, not a prostate-specific clinical effect — there are no prostate-outcome human studies. OHM grade: D / provisional.
Real-world protocol
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Prostamax, and no prostate-outcome human data exists to inform a protocol around. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Prostamax specifically, let alone for a prostate-support outcome.
Side effects & management
No adverse-event data exists for Prostamax. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and a peptide marketed on an organ-specific claim it has no clinical outcome data for is an especially easy target for overselling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Prostamax is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Prostamax kept D-provisional / encyclopedia-only.
- PMIDs: 23221144 (Dzhokhadze et al. 2012, also the sequence-pinning citation), 15085253 (Khavinson/Lezhava/Malinin 2004), 19359734, 15612551 — all.
- Related: Testagen · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Prostamax kept D-provisional / encyclopedia-only.
- PMIDs: 23221144 (Dzhokhadze et al. 2012, also the sequence-pinning citation), 15085253 (Khavinson/Lezhava/Malinin 2004), 19359734, 15612551 — all.
- Related: Testagen · the Khavinson bioregulator family.